Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Aug

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Amit Sanyal, MD: A Clinician’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Digital Integrative Medicine Program Improves Overall Survival in Patients Undergoing Systemic Cancer Treatment

Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events

Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital

Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?

Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer